ObsEva to Present at the H.C. Wainwright BioConnect 2022 Conference
ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company focused on women's reproductive health, announced a corporate update presentation during the H.C.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company focused on women's reproductive health, announced a corporate update presentation during the H.C. Wainwright BioConnect Conference from January 10-13, 2022. The presentation will be available on-demand starting at 7 a.m. EST on January 10, 2022. Additionally, a webcast will be accessible after the event on the company's website under Events Calendar. ObsEva is advancing therapies for uterine fibroids, endometriosis, and preterm labor.
Details
News Market Reaction – OBSV
The recorded move for OBSV in the trading session of this news was +9.05%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
GENEVA, Switzerland January 3, 2022 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that Company Management will provide a corporate update at the upcoming H.C. Wainwright BioConnect Conference, to be held January 10-13, 2022.
The presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7 a.m. EST on Monday, January 10, 2022.
A webcast can be accessed here and will also be accessible under “Events Calendar” in the investors section of ObsEva’s website, starting Friday, January 14, 2022.
About ObsEva
ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on new therapies for the treatment of uterine fibroids, endometriosis, and preterm labor. ObsEva is listed on the Nasdaq Global Select Market and is traded under the ticker symbol “OBSV” and on the SIX Swiss Exchange where it is traded under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com
For further information, please contact:
CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550
Investor Contact
Joyce Allaire
jallaire@lifesciadvisors.com
+1 (617) 435-6602
Attachment
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.